NCT01959945View on ClinicalTrials.gov

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

PHASE3CompletedINTERVENTIONAL

Enrollment

219

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

October 31, 2014

Conditions

Influenza

Interventions

BIOLOGICAL

Flublok® Quadrivalent Influenza Virus Vaccine

Intramuscular (Relevant year formulation)

BIOLOGICAL

Fluarix Quadrivalent® Influenza Virus Vaccine

Intramuscular (Relevant year formulation)

Trial Locations (1)

04210

Maine Research Associates, LLC, Auburn

All Listed Sponsors

lead

Protein Sciences Corporation

INDUSTRY

NCT01959945 - Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation) | Biotech Hunter | Biotech Hunter